Can we move towards personalised pancreatic cancer therapy?

Jamieson, N. B. , Chang, D. K. , Grimmond, S. M. and Biankin, A. V. (2014) Can we move towards personalised pancreatic cancer therapy? Expert Review of Gastroenterology and Hepatology, 8(4), pp. 335-338. (doi: 10.1586/17474124.2014.893820) (PMID:24702631)

Abstract

Pancreatic ductal adenocarcinoma remains an unyielding adversary, with a 5-year survival of 5%, a figure unchanged in 50 years. Characterised by marked genetic heterogeneity, recent genomic sequencing efforts demonstrate that with the exclusion of a few known mutations, most mutations occur at a prevalence of <5%. Current systemic chemotherapeutics, when used in an all-comer approach, are at best modestly effective, yet are associated with responses in small groups of undefined patients. Defining these subgroups and targeting them with the appropriate therapy in a personalized or stratified approach holds the promise of improved outcomes for this disease.

• Item Type: Articles (Editorial)
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Jamieson, Professor Nigel and Biankin, Professor Andrew and Grimmond, Professor Sean and Chang, Professor David
• Authors: Jamieson, N. B., Chang, D. K., Grimmond, S. M., and Biankin, A. V.
• College/School: College of Medical Veterinary and Life Sciences > School of Cancer Sciences; College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
• Journal Name: Expert Review of Gastroenterology and Hepatology
• Publisher: Expert Reviews
• ISSN: 1747-4124